Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

LH vs HOLX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HOLX Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 5–5 Matrix Metrics)

HOLX Overall Winner 6-Pillar Tally: LH 2 – 4 HOLX Matrix Metrics: LH 5 – 5 HOLX

As of Nov 20, 2026, Hologic Inc (HOLX) is the stronger overall head-to-head candidate over Labcorp Holdings Inc. (LH) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). LH carries a Unified Composite Score of 44.1/100 (HOLD) at $367.13 (18.7x Forward P/E, 11.2% operating margin), whereas HOLX carries 64.2/100 (BUY) at $76.01 (20.1x Forward P/E, 23.0% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About LH vs HOLX
LH NYSE
Labcorp Holdings Inc.
Services-Medical Laboratories
$367.13
-0.47% 1D
Market Cap $30.0B
TTM Revenue $14.6B
Forward P/E 18.7x
Beta / 30D Vol 0.33β · 35% Vol
Unified Composite Score
44.1 / 100 HOLD
Tech 25.0 Fund 35.0 Flow 51.0 Mom 31.1
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (4.4% over 20 days), RSI 62
RSI-14: 62.3 · SMA20: $363.16 · SMA50: $334.76
HOLX NASDAQ Head-to-Head Winner
Hologic Inc
X-Ray Apparatus & Tubes & Related Irradiation Apparatus
$76.01
+0.48% 1D
Market Cap $16.9B
TTM Revenue $4.13B
Forward P/E 20.1x
Beta / 30D Vol 0.08β · 3% Vol
Unified Composite Score
64.2 / 100 BUY
Tech 75.0 Fund 61.0 Flow 54.0 Mom 49.2
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 69
RSI-14: 69.0 · SMA20: $75.47 · SMA50: $75.29

6-Pillar Scorecard Institutional Category Breakdown (LH 2 – 4 HOLX)

Columns: Metric · LH · HOLX
1. Valuation Multiples LH
Forward P/E 18.7x 20.1x
Trailing P/E 30.2x 31.4x
PEG Ratio 1.21x 1.66x
EV / Revenue 2.5x 4.1x
2. Growth & Scale LH
Revenue Growth (YoY) +6.9% +2.5%
Earnings Growth (YoY) +3.2% -9.2%
TTM Revenue (USD) $14.6B $4.13B
Market Cap $30.0B $16.9B
3. Profitability & Quality HOLX
Gross Margin 29.0% 60.4%
Operating Margin 11.2% 23.0%
Net Profit Margin 6.9% 13.2%
Return on Equity (ROE) 11.4% 10.9%
4. Balance Sheet & Cash Flow HOLX
Cash Generation (TTM) $1.29B $1.35B EBITDA
Cash Flow Margin 8.8% 32.7% EBITDA Mgn
Net Cash / Leverage $6.51B Net Debt (0.77x D/E) $23.51 Book/Sh · 10.9% ROE
Dividend Yield 0.78% None (0.00%)
5. Options & Positioning HOLX
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 76.5% (44th %ile) 6.3% (3rd %ile)
Put/Call OI Skew 0.06x (Call-Skewed) 6.20x (Put-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat HOLX
OpEx & R&D Intensity 17.8% of Rev ($2.60B) 37.4% of Rev ($1.54B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Diagnostics & Research Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: LH (5) vs HOLX (5)
Institutional Metric LH HOLX Criterion Row Edge
Market Capitalization
Scale
$30.0B $16.9B Larger Scale LH
Trailing P/E Ratio
Valuation
30.2x 31.4x Lower Multiple LH
Forward P/E Ratio
Valuation
18.7x 20.1x Lower Multiple LH
Revenue Growth (YoY)
Growth
+6.9% +2.5% Higher Growth LH
Operating Margin (TTM)
Profitability
11.2% 23.0% Higher Margin HOLX
Net Profit Margin
Profitability
6.9% 13.2% Higher Margin HOLX
Return on Equity (ROE)
Capital Efficiency
11.4% 10.9% Higher ROE LH
52-Week Range Position
Momentum
94% ($245–$375) 100% ($52–$76) Stronger Trend HOLX
Beta / 30D Volatility
Risk Regime
0.33β · 35% Vol 0.08β · 3% Vol Lower Realized Risk HOLX
Unified Institutional Score
Composite Signal
44.1 / 100 (HOLD) 64.2 / 100 (BUY) Higher Composite HOLX
Trailing 12M Revenue (USD)
Operating Scale
$14.6B $4.13B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
29.0% 60.4% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.21x PEG · 2.5x EV/Rev 1.66x PEG · 4.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.29B ($6.51B Net Debt (0.77x D/E)) $1.35B EBITDA ($23.51 Book/Sh · 10.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon HOLX +0.87 pp
LH: -0.53% · HOLX: +0.34%
3M Horizon LH +7.12 pp
LH: +9.06% · HOLX: +1.94%
6M Horizon LH +2.86 pp
LH: +5.34% · HOLX: +2.48%
1Y Horizon LH +2.86 pp
LH: +5.34% · HOLX: +2.48%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on LH vs HOLX. Trailing 12-month operating profitability (LH 11.2% vs HOLX 23.0%) and valuation multiples (LH 18.7x vs HOLX 20.1x Forward P/E) are benchmarked directly in Pillar 4 below.

LH ADR TTM Benchmark FX-Normalized USD
TTM Revenue$14.6B
Gross Margin29.0%
Op. Margin11.2%
ROE / Fwd P/E11.4% · 18.7x
HOLX ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.13B
Gross Margin60.4%
Op. Margin23.0%
ROE / Fwd P/E10.9% · 20.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
LH CONSOLIDATION
63d in phase · OBV NEUTRAL
Current IV 76.5%
IV Percentile 44th %ile
Put/Call OI Skew 0.06x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact LH Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
HOLX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 6.3%
IV Percentile 3rd %ile
Put/Call OI Skew 6.20x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow NEUTRAL
Exact HOLX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
LH Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $30.0B market capitalization and 11.2% operating margin.
OpEx & R&D Reinvestment 17.8% of Rev ($2.60B)
90D Engineering Disclosures 0 Published
HOLX Moat Profile Scale & Operating Efficiency Moat
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $16.9B market capitalization and 23.0% operating margin.
OpEx & R&D Reinvestment 37.4% of Rev ($1.54B)
90D Engineering Disclosures 0 Published

Investor FAQ LH vs HOLX Key Questions & Quantitative Answers

As of Nov 20, 2026, Hologic Inc (HOLX) is the stronger overall head-to-head candidate over Labcorp Holdings Inc. (LH) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Profitability & Quality, Balance Sheet & Cash Flow, Options & Positioning). LH carries a Unified Composite Score of 44.1/100 (HOLD) at $367.13 (18.7x Forward P/E, 11.2% operating margin), whereas HOLX carries 64.2/100 (BUY) at $76.01 (20.1x Forward P/E, 23.0% operating margin). Technically, LH sits in a Markup phase (RSI 62.3, CONSOLIDATION options structure) and HOLX sits in a Neutral phase (RSI 69.0, UNCLASSIFIED options structure).

LH leads the Growth & Scale pillar: LH posts +6.9% YoY revenue growth and +3.2% YoY earnings growth on $14.6B TTM revenue (29.0% gross margin, 11.2% operating margin), compared with HOLX at +2.5% YoY revenue growth and -9.2% YoY earnings growth on $4.13B TTM revenue (60.4% gross margin, 23.0% operating margin). On trailing 12-month operating scale, LH generates $14.6B in USD-normalized revenue versus $4.13B for HOLX. In operating R&D and SG&A reinvestment, LH deploys 17.8% of Rev ($2.60B) (0 90-day corporate R&D disclosures) versus 37.4% of Rev ($1.54B) (0 disclosures) for HOLX.

LH screens cheaper on headline valuation multiples. LH trades at 18.7x Forward P/E, 30.2x Trailing P/E, 1.21x PEG, and 2.5x EV/Revenue (8.8% FCF margin), whereas HOLX trades at 20.1x Forward P/E, 31.4x Trailing P/E, 1.66x PEG, and 4.1x EV/Revenue (32.7% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against LH (11.4% ROE) versus HOLX (10.9% ROE) capital efficiency.

In options market volatility and institutional positioning, LH carries 76.5% implied volatility (44th %ile, Balanced (25th–60th %ile)), a 0.06x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (0.33β · 35% Vol realized risk). By comparison, HOLX carries 6.3% implied volatility (3rd %ile, Compressed (<25th %ile)), a 6.20x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.08β · 3% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.